Get the Stockscreener App
0.9034
0.46%
-0.0042
After Hours:
.95
0.0466
+5.16%
Lucid Diagnostics Inc stock is traded at $0.9034, with a volume of 1.38M.
It is down -0.46% in the last 24 hours and down -16.35% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.9076
Open:
$0.9128
24h Volume:
1.38M
Relative Volume:
1.00
Market Cap:
$172.34M
Revenue:
$4.71M
Net Income/Loss:
$-58.01M
P/E Ratio:
-1.0972
EPS:
-0.8234
Net Cash Flow:
$-46.68M
1W Performance:
-6.80%
1M Performance:
-16.35%
6M Performance:
-25.95%
1Y Performance:
-18.61%
1-Day Range:
$0.9001
$0.9389
1-Week Range:
$0.9001
$0.9979
52-Week Range:
$0.90
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.9034 | 173.14M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lucid Diagnostics Market Sentiment - Benzinga España
TradingKey - TradingKey
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LUCD|Lucid Diagnostics Inc|Price:0.908|Chg%:-0.038 - TradingKey
AAPL: Apple Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Lucid Diagnostics Inc (LUCD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lucid Diagnostics (LUCD) Drops 6.4% to $0.95 – Testing Key SupportAnalyst Upgrade Stocks - dars.gov.et
Lucid Diagnostics (LUCD) Nears One-Dollar Threshold After Modest DeclineArms Index - dars.gov.et
LUCD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lucid Diagnostics (LUCD) Holds Steady Near Support: Can the Modest Uptick Signal a Reversal?Volume Breadth - dars.gov.et
LUCD Q1 2026 Earnings: Significant EPS Miss and No Reported Revenue Raise ConcernsTech Earnings Analysis - dars.gov.et
Lucid Diagnostics (LUCD) Extends Decline: Approaching Key Support at $0.99 After 3.7% DropKeltner Channel - dars.gov.et
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - GuruFocus
LUCD Q1 2026 Earnings: Significant Earnings Miss as Company Reports No RevenueEstimate Accuracy - DonanımHaber
PAVmed gets 180-day extension to regain Nasdaq listing compliance - MSN
Lucid Diagnostics (LUCD) Edges Higher as Diagnostics Sector Sees Renewed InterestStop Loss Guidance - dars.gov.et
Lucid Diagnostics: Positioned For A Medicare-Driven Inflection (NASDAQ:LUCD) - Seeking Alpha
LUCD News | LUCID DIAGNOSTICS INC (NASDAQ:LUCD) - ChartMill
Lucid Diagnostics Inc.(NasdaqCM:LUCD) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Lucid Diagnostics Inc.(NasdaqCM: LUCD) dropped from Russell 3000 Value Benchmark - marketscreener.com
Lucid Diagnostics Inc.(NasdaqCM: LUCD) dropped from Russell 2500 Value Benchmark - marketscreener.com
Lucid Diagnostics Inc.(NasdaqCM: LUCD) dropped from Russell 2000 Value Benchmark - marketscreener.com
Lucid Diagnostics Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue Challenges - dars.gov.et
Lucid Diagnostics Inc.(NasdaqCM:LUCD) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Lucid Diagnostics Inc. Actuals & Estimates (NASDAQ:LUCD) - TradingView
LUCD Forecast — Price Target — Prediction for 2027 - TradingView
Lucid Diagnostics Shareholders Approve Stock Authorization Increase - TipRanks
Lucid Diagnostics (LUCD) boosts authorized shares to 400M and re-elects directors - Stock Titan
LUCD: All proposals passed, including director elections and share authorization increase - TradingView
Transcript : Lucid Diagnostics Inc.Shareholder/Analyst Call - marketscreener.com
Lucid Diagnostics (LUCD) Holds Steady at $1.03: Stock Consolidates Near Key LevelsPre-Earnings Momentum - dars.gov.et
Lucid Diagnostics Inc (LUCD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LUCD Q1 2026 Earnings: Wider-Than-Expected Loss Drives Stock Despite No RevenueSubscription Growth Report - dars.gov.et
Top Lucid Diagnostics (LUCD) Competitors 2026 - MarketBeat
Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lucid Diagnostics Inc (LUCD) Valuation: PE, PB & Fair Value Analysis - TradingKey
LUCD Q1 2026 Earnings: Deep EPS Miss Masks Operational Progress; Stock Edges HigherQuarterly Earnings - DonanımHaber
Lucid Diagnostics (LUCD) Edges Higher, Testing Key Resistance at $1.05Risk Reward Setups - dars.gov.et
LUCD Q1 2026 Earnings: EPS Misses Estimates by 100.7% as Company Reports No RevenueEarnings Turnaround - dars.gov.et
Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026. - marketscreener.com
Lucid Diagnostics misses on revenue, but 2026 growth outlook lights up bull case - MSN
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case - Benzinga
LUCD Maintained by Ascendiant Capital -- Price Target Raised to $9.25 - GuruFocus
LUCD Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue Development StageEBITDA Estimate Trend - dars.gov.et
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results - Yahoo Finance
Lucid Diagnostics Q1 2026 Earnings: EPS Miss Widens as Company Reports Wider-Than-Expected LossManagement Tone Analysis - dars.gov.et
LUCD Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue Stage ChallengesRevenue Warning Signal - The Legal Advocate
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):